The cell-specific anti-proliferative effect of reduced glutathione is mediated by γ-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions

International Journal of Cancer

Volumn 71, Issue 2, 1997, Pages 246-250

  Perego, Paola ^a   Paolicchi, Aldo ^b   Tongiani, Roberto ^b   Pompella, Alfonso ^c   Tonarelli, Patrizia ^b   Carenini, Nives ^a   Romanelli, Simona ^a   Zunino, Franco ^a,d  

^a Istituto per la Ricerca e la Cura Dei Tumori   (Italy)

^b UNIVERSITY OF PISA   (Italy)

^c UNIVERSITY OF SIENA   (Italy)

^d NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE PEROXIDASE; GLUTATHIONE REDUCTASE; GLUTATHIONE TRANSFERASE;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; ENZYME ACTIVITY; ENZYME ASSAY; HUMAN; HUMAN CELL; MALIGNANT NEOPLASTIC DISEASE; OXIDATION; PRIORITY JOURNAL;

CATALASE; CELL DIVISION; DITHIOTHREITOL; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUTATHIONE; GLUTATHIONE TRANSFERASE; HUMANS; HYDROGEN PEROXIDE; ISOXAZOLES; OVARIAN NEOPLASMS; OXIDATION-REDUCTION; TUMOR CELLS, CULTURED;

EID: 0030970686     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0215(19970410)71:2<246::AID-IJC20>3.0.CO;2-E     Document Type: Article

References (35)

1. BEHRENS, B.C., HAMILTON, T.C., MASUDA, H., GROTZINGER, K.R., WHANGPENG, J., LOUIE, K.G., KNUTSEN, T., MCKOY, W.M., YOUNG, R.C. and OZOLS, R.F., Characterization of a cis-diamminedichloroplatinum(II)-resistant human ovarian cancer cell line and its use in evaluation of platinum analogues. Cancer Res., 47, 414-418 (1987).
2. BÉNARD, J., DA SILVA, J., DE BLOIS, M.C., BOYER, P., DUVILLARD, P., CHIRIC, E. and RIOU, G., Characterization of a human ovarian adenocarcinoma line, IGROV-1, in tissue culture and in nude mice. Cancer Res., 45, 4970-4979 (1985).
3. COOK, J.R., HUANG, D.P., BURKHARDT, A.L., GOLDMAN, M.E., CARROLL, M., BRESNICK, E. and CHIU, J.F., Assessment of the anti-tumor potential of glutathione. Cancer Lett., 21, 277-283 (1984).
4. DI RE, F., BOHM, S., ORIANA, S., SPATTI, G.B., PIROVANO, C., TEDESCHI, M. and ZUNINO, F., High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. Ann. Oncol., 4, 55-61 (1993).
5. GELVAN, D., MORENO, V., CLOPTON, D.A., CHEN, Q. and SALTMAN, P., Sites and mechanisms of low-level oxidative stress in cultured cells. Biochem. biophys. Res. Commun., 206, 421-428 (1995).
6. GODWIN, A.K., MEISTER, A., O'DWYER, P.J., HUANG, C.S., HAMILTON, T.C. and ANDERSON, M.E., High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc. nat. Acad. Sci. (Wash.), 89, 3070-3074 (1992).
7. GUEHMANN, S., VORBRUEGGEN, G., KALKBRENNER, F. and MOELLING, K., Reduction of a conserved Cys is essential for Myb DNA-binding. Nucleic Acids Res., 20, 2279-2286 (1992).
8. HAINAUT, P. and MILNER, J., Redox modulation of p53 conformation and sequence specific DNA-binding in vitro. Cancer Res., 53, 4469-4473 (1993).
9. HAMERS, F.P.T., BRAKKEE, J.H., CAVALLETTI, E., TEDESCHI, M., MARMONTI, L., PEZZONI, G., NEIJT, J.P. and GISPEN, W.H., Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res., 53, 544-549 (1993).
10. HANIGAN, M.H., FRIERSON, H.F., BROWN, J.E., LOVELL, M.A. and TAYLOR, P.T., Human ovarian tumors express γ-glutamyl transpeptidase. Cancer Res., 54, 286-290 (1994a).
11. HANIGAN, M.H., GALLAGHER, B.C., TAYLOR, P.T. and LARGE, M.K., Inhibition of γ-glutamyl transpeptidase activity by acivicin in vivo protects the kidney from cisplatin-induced toxicity. Cancer Res., 54, 5925-5929 (1994a).
12. HANIGAN, M.H. and RICKETTS, W.A., Extracellular glutathione is a source of cysteine for cells that express gamma-glutamyltranspeptidase. Biochemistry, 32, 6302-6306 (1993).
13. HUSEBY, N.B. and STRÖMME, J.H., Practical points regarding routine determination of γ-glutamyl transferase (γ-GT) in serum with a kinetic method at 37°C. Scand. J. clin. Lab. Invent., 34, 357-361 (1974).
14. KARMALI, R.A., Growth inhibition and prostaglandin metabolism in the R3230AC mammary adenocarcinoma by reduced glutathione. Cancer Biochem. Biophys., 7, 147-154 (1984).
15. MEIJER, C., MULDER, N.H. and DE VRIES, E.G.E., The role of detoxifying systems in resistance of tumor cells to cisplatin and adriamycin. Cancer Treat. Rev., 17, 389-407 (1990).
16. MEISTER, A., Glutathione, ascorbate and cellular protection. Cancer Res., 54, 1969s-1975s (1994).
17. MISRA, H.P., Generation of Superoxide free radical during the autoxidation of thiols. J. biol. Chem., 249, 2151-2155 (1974).
18. NEAL, G.E. and LEGG, R.F., The ineffectiveness of reduced glutathione in preventing the development of liver tumors from aflatoxin-induced preneoplastic liver lesions. Cancer Lett., 21, 83-87 (1983).
19. 1-induced hepatocellular carcinomas by reduced glutathione. Science, 212, 541-542 (1980).
20. PEREGO, P., GIAROLA, M., RIGHETTI, S.C., SUPINO, R., CASERINI, C., DELIA, D., PIEROTTI, M.A., MIYASHITA, T., REED, J.C. and ZUNINO, F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res., 56, 556-562 (1996).
21. PRATESI, G., DAL BO, L., PAOLICCHI, A., TONARELLI, P., TONGIANI, R. and ZUMNIO, F., The role of the glutathione-dependent system in tumor sensitivity to cisplatin: a study of human tumor xenografts. Ann. Oncol., 6, 283-289 (1995).
22. ROSS, D., MOLDEUS, P., SIES, H. and SMITH, M.T., Mechanism and relevance of glutathione mutagenicity. Mutat. Res., 175, 127-131 (1986).
23. ROWLEY, D.A. and HALLIWELL, B., Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett., 138, 33-36 (1982).
24. STARK, A.-A., PAGANO, D.A., GLASS, G., KAMIN-BELSKY, N. and ZEIGER, E., The effects of anti-oxidants and enzymes involved in glutathione metabolism on mutanenesis by glutathione and L-cysteine. Mutat. Res., 30, 215-222 (1994).
25. STARK, A-A., ZEIGER, E. and PAGANO, D.A., Glutathione mutagenesis in Salmonella typhimurium TA100 is a γ-glutamyltranspeptidase-enhanced process involving active oxygen species. Carcinogenesis, 9, 771-777 (1988).
26. STARK, A.A., ZEIGER, E. and PAGANO, D.A., Glutathione metabolism by gamma-glutamyltranspeptidase leads to lipid peroxidation: characterization of the system and relevance to hepatocarcinogenesis. Carcinogenesis, 14, 183-189(1993).
27. SUZUKI, Y., LYALL, V., BIBER, T.U.L. and FORD, G.D., A modified technique for the measurement of sulfhydryl groups oxidized by reactive oxygen intermediates. Free Radic. Biol. Med., 9, 479-484 (1990).
28. TATE, S.S. and MEISTER, A., Serine-borate complex as a transition-state inhibitor of γ-glutamyl transpeptidase. Proc. nat. Acad. Sci. (Wash.), 75, 4806-4809 (1978).
29. TEDESCHI, M., DE CESARE, A., ORIANA, S., PEREGO, P., SILVA, A., VENTURINO, P. and ZUNINO, F., The role of glutathione in combination with cisplatin in the treatment of ovarian cancer. Cancer Treat. Rev., 18, 253-259 (1991).
30. THUST, R. and BACH, B., Exogenous glutathione induces sister chromatid exchanges, clastogenicity and endoreduplication in V79-E Chinese hamster cells. Cell Biochem. Toxicol., 1, 123-131 (1985).
31. TIEN, M., BUCHER, J.R. and AUST, S.D., Thiol-dependent lipid peroxidation. Biochem. biophys. Res. Commun., 107, 279-285 (1982).
32. VAN DER VLIET, A. and BAST, A., Effect of oxidative stress on receptors and signal transmission. Chem.-biol. Interact., 85, 95-116 (1992).
33. VERSANTVOORT, C.H.M., BROXTERMAN, H.J., BAGRIJ T., SCHEPER, R.J. and TWENTYMAN, P.R., Regulation by glutathione of drug transport in multidrug-resistant human lung-tumour cell lines over-expressing multidrug resistance-associated protein. Brit. J. Cancer, 72, 82-89 (1995).
34. ZUNINO, F., DE CESARE, M., ORIANA, S., PEKEGO, P., PASINI, A. and TEDESCHI, M., The role of GSH incisplatin therapy. Proceedings of the First European Workshop on Glutathione. Bull Soc. luxemb. Biol. clin., (special issue), 121-132 (1993).
35. ZUNINO, F., PRATESI, G., MICHELONI, A., CAVALLETTI, E., SALA, F. and TOFANETTI, O., Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the anti-tumor drug. Chem.-biol. Interact., 70, 89-101 (1989).